CRSw/nNP
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. The patient should be voluntary to take part in the trial, understand and agree to take the drugs, accept follow-ups and report the events properly. And the inform consent should be signed; 2. Aged between 18 and 70 years old; 3. Male or female, Chinese people; 4. With the diagnosis of CRSw/nNP according to EP3OS 2007: Subjective objectives: presence of two or more symptoms one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip): +/- facial pain/pressure; +/- reduction or loss of smell; for > 12 weeks; Endoscopy: with/without polyps bilateral in middle meatus, purulent secretionin the middle meatus, with/without middle meatus swelling or mucous block; Image: coronal CT scan, with/without mucous change in OMC/sinus (only for reference).
Exclusion criteria
Exclusion criteria: 1. Allergy to clarithromycin or topical sterouid spray; 2. With any one of the following diseases: cystic fibrosis based on positive sweat test or DNA alleles; gross immunodeficiency (congenital or acquired); congenital mucociliary problems eg primary ciliary dyskinesia (PCD); non-invasive fungal balls and invasive fungal disease; systemic vasculitis and granulomatous diseases; cocaine abuse; neoplasia; 3. Treated with other CRS medicines 4 weeks before inclusion, such as macrolides or steroids; or other treatment, such as nasal lavage or desensitive treatment; 4. Comorbidity with asthma or other gross immunodeficiency, using steroid through the nose or inhalation or systemically; 5. With upper respiratory tract infection; 6. With severe systemic diseases affecting the cardiovascular, metabolic, immunology, neurology, hematology, cerebrovascular or respiratory system; 7. Participate in other clinical researches within the lastest 30 days or the reseacher themselves; 8. With history of psychic disease, or mental problems; 9. Pregnant or breast-feeding females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical symtom; | — |
Secondary
| Measure | Time frame |
|---|---|
| endoscopic examination;paranasal sinus CT; | — |
Countries
China